INTRODUCTION {#S1}
============

Neonatal immune systems can respond equally well or better than adults to vaccines against several pathogens, including malaria ([@R14]), measles ([@R22]), hepatitis B ([@R100]), and bacillus Calmette-Guérin (BCG) ([@R136]). However, the neonatal response to other vaccines has been reported to be inferior to that of older children ([@R42]; [@R49]; [@R151]). The immune system of infants and young children has also been shown to be capable of generating vaccine-induced protection against pathogens such as enterovirus 71 (EV71) ([@R157]).

While the prenatal environment is relatively sterile compared to that of adults ([@R95]; [@R96]), the immune cells of neonates adapt to respond quickly to pathogens ([@R82]). However, immune cells of neonates and adults have phenotypic and functional differences due to the immaturity of the neonatal immune system ([@R4]; [@R65]; [@R66]; [@R67]; [@R89]; [@R105]; [@R125]; [@R142]; [@R145]; [@R32]).

HIV-1 envelope (Env) gp120 immunogens have elicited plasma-binding antibody responses in human and monkey neonates ([@R27]; [@R41]; [@R60]; [@R64]; [@R85], [@R86]; [@R87]; [@R103]). Infants vaccinated with the Chiron recombinant HIV-1 gp120 with MF59 adjuvant generated higher immunoglobulin G (IgG) levels against the first and second variable loops (V1V2) than adults, which is important, since V2 antibody responses were associated with reduced risk of HIV-1 acquisition in the RV144 vaccine trial ([@R41]; [@R56]; [@R87]). However, it is unclear if neonates respond as well as adults to well-folded soluble, stabilized HIV-1 Env trimers ([@R111]), which have been shown to induce autologous tier 2 neutralizing antibodies in adult rhesus macaques and weak heterologous neutralizing antibodies in rabbits ([@R51]; [@R101]; [@R114]).

To date, broadly neutralizing antibodies (bnAbs) are not consistently elicited following HIV-1 Env vaccination but are generated in \~50% of HIV-1 infected adults only after several years of infection, with accumulation of high levels of antibody mutations ([@R17]; [@R36]; [@R52]; [@R59]; [@R75]). Recent reports suggest that bnAb induction occurs in HIV-1-in-fected infants with faster kinetics and lower somatic mutations ([@R47]; [@R91]; [@R126]). Thus, if neonatal and pediatric immune systems respond in an accelerated or more permissive manner to Env forms, this may create a window of opportunity between birth and puberty to generate durable immunity to HIV-1 by vaccination with an appropriate Env regimen.

We previously identified sequential Envs associated with the induction and maturation of CD4-binding site (CD4bs) bnAbs in the HIV-1-infected individual CH505 who was followed from early infection to the development of bnAbs ([@R16]; [@R43]; [@R75]). CH505 transmitted-founder (T/F) Env was the first autologous Env found to initiate CD4bs bnAb lineages in humans ([@R76]), and the CH505 T/F and evolved sequential Env variants have been shown to be immunogenic in bnAb knockin mice and adult macaques ([@R114]; [@R147]). These CH505 Env variants are being tested in adults in the HIV Vaccine Trials Network (HVTN) 115 trial ([https://clinicaltrials.gov](https://clinicaltrials.gov/) identifier [NCT03220724](https://clinicaltrials.gov/ct2/show/NCT03220724)), and a trial in neonates is being planned (HVTN 135).

Here, we immunized neonatal and adult macaques with HIV-1 CH505 gp120 or SOSIP trimer immunogens to compare the ability of neonatal and adult macaque immune systems to respond to these Env immunogen forms. We found that immunization of neonatal macaques with trimeric HIV-1 CH505 Envs induced plasma antibody titers that increased more rapidly in neonatal macaques than adult macaques. Increased frequencies of activated circulating T follicular helper-like (Tfh) cells following Env immunization were observed in immunized neonatal macaques compared to adults. Moreover, single-cell transcriptomic analysis of neonatal versus adult blood immune cells showed distinct transcriptomes, with elevated *BCL2* in T cells and lower interleukin-10 (IL-10) receptor alpha (*IL10RA*) transcripts in post-vaccination neonatal T, B, and natural killer (NK) cells and monocytes, suggesting a more permissive immune environment in macaque neonates for initiation of HIV-1 Env B cell lineages.

RESULTS {#S2}
=======

Vaccine-Induced Antibody Responses to HIV-1 Envs in Macaque Neonates versus Adults {#S3}
----------------------------------------------------------------------------------

Three groups of neonatal and adult macaques were vaccinated with either HIV-1 CH505 gp120s or CH505 gp140 SOSIP trimers ([@R114]; [@R147]). The first group of neonatal (N = 4) and adult (N = 4) ([@R147]) macaques received sequential 4-valent CH505 gp120s ([@R147]) in the Toll-like receptor 4 (TLR4) agonist adjuvant glucopyranosyl lipid-A (GLA) in a stable, oil-in-water emulsion (GLA-SE) ([@R120]) (study 1) ([Figure 1A](#F1){ref-type="fig"}). The study 1 sequential gp120 regimen is being tested in humans in the HVTN 115 clinical trial ([NCT03220724](https://clinicaltrials.gov/ct2/show/NCT03220724)).

The second group of neonatal (N = 3) and adult (N = 4) macaques was immunized with sequential 4-valent CH505 gp140 SOSIP trimers (CH505 SOSIPs) ([@R114]) combined with the TLR4 agonist adjuvant, GLA-SE (study 2) ([Figure 1A](#F1){ref-type="fig"}; [@R114]). CH505 SOSIPs were antigenic for V1V2-glycan, CD4bs, and V3-glycan bnAbs ([@R114]).

The third group of neonatal (N = 2) and adult (N = 4) macaques (study 3) received the sequential CH505 gp140 SOSIP trimer Envs (stabilized CH505 SOSIPs) combined with the TLR3 agonist adjuvant polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC) ([Figure 1A](#F1){ref-type="fig"}; [@R114]; [@R29]). In study 3, animals also received two priming doses of DNA gp145 expressing CH505 T/F prior to sequential CH505 SOSIPs ([@R114]). Due to the small sample size and similar plasma and cellular immune response profiles within CH505-SOSIP-immu-nized animals in studies 2 and 3, we combined these groups for select comparisons in neonates versus adults.

In study 1, plasma from neonatal and adult macaques immunized with gp120 Envs bound autologous CH505 T/F gp120 Env at similar average titers and mapped predominantly to the third variable region (V3), C1, loop D, and CD4bs epitopes ([Figures 1A](#F1){ref-type="fig"}, [S1A](#SD1){ref-type="supplementary-material"}, and [S1B](#SD1){ref-type="supplementary-material"}). It should be noted that neonates in study 1 immunized with gp120 Envs received two more gp120 vaccines than adults beyond five immunizations, but the animals appeared to be hyperimmunized and did not show rises in titers beyond five immunizations. Thus, the data show similar binding titers to immunizing Env regardless of the extra two immunizations in neonates.

In neonatal macaques immunized with CH505 SOSIP trimers (studies 2 and 3), we compared the plasma-binding levels across three time points (2 weeks after the first, second, and sixth immunizations) using nonparametric analyses of longitudinal data with time (three time points) and group (neonate versus adult) as factors. We observed a more rapid increase in gp120 antibody responses in neonates over adults that was more striking between weeks 2 and 30 in study 3, compared to study 2, where the difference was only more striking after week 10 ([Figure 1A](#F1){ref-type="fig"}). Due to the small sample size within SOSIP-immunized animals in studies 2 and 3, we could not conduct a stratified statistical analyses and thus combined these groups for comparisons and found a statistically significant increase in plasma binding to gp120 protein in neonates compared with adult macaques based on the group-by-time interaction (p = 0.038) (see [STAR Methods](#S11){ref-type="sec"}). Additionally, we found that neonate macaques in studies 2 and 3 generally showed higher levels of plasma gp120 and gp41 antibodies over time compared to adults ([Figure 1](#F1){ref-type="fig"}). That neonates immunized with SOSIP trimers displayed similarly low levels of SOSIP-binding antibodies, but higher gp120 and gp41 responses suggest exposure of immunodominant sites on the trimer *in vivo* following immunization. Alternatively, another explanation for increased gp41 antibody responses in neonates compared to adult macaques may be associated with a more cross-reactive nature of neonate compared to adult B cells ([@R20]; [@R81]; [@R104]; [@R30]) and that gp41 antibodies have been shown to be cross-reactive ([@R50]; [@R146]). However, we did not confirm the origin of the gp41 antibody responses that appeared to be higher in neonates than adult macaques.

It was of interest to determine if the B cell repertoires were the same or different in neonates versus adults with gp120 immunogens that are currently in the HVTN 115 clinical trial ([NCT03220724](https://clinicaltrials.gov/ct2/show/NCT03220724)). Moreover, CH505 TF Env is planned for testing in human neonates by the HVTN. To compare blood-Env-specific memory B cell repertoires in eight adult macaques that recieved sequential CH505 Env vaccine regimes ([@R147]) with those in neonatal macaques, in study 1, we evaluated the B cell repertoire in four 4-valent gp120-immunized neonatal macaques after the fourth immunization (week 20) in the sequential Env vaccination regimen using HIV-1 Env-specific single memory B cell sorting with fluorophore-labeled recombinant CH505 transmitted/founder (T/F) gp120 proteins. We found that the mean immunoglobulin (Ig) heavy-chain variable region (IGHV) nucleotide mutation frequencies and heavy-chain CDR3 (HCDR3) lengths of HIV-1 Env-reactive CD4bs and non-CD4bs-targeted monoclonal antibodies (mAbs) from neonatal and adult macaques were not statistically different (p \> 0.05, exact Wilcoxon test) ([Figures 1B](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"}). Thus, after four immunizations in study 1, neonatal and adult antigen-specific B cell repertoires acquired similar levels of somatic mutations with comparable immunoglobulin HCDR3 lengths, suggesting that neonatal macaques have similarly diverse B cell repertoires in response to gp120 Envs as adult macaques.

Plasma from each study of neonatal and adult macaques neutralized tier 1 autologous (CH505 w4.3) and heterologous HIV-1 isolates but did not neutralize the autologous tier 2 CH505 T/F virus ([Figure S1C](#SD1){ref-type="supplementary-material"}). Plasma from studies 1--3 of neonate and adult rhesus macaques neutralized tier 2 virus B.JR-FL produced in the presence of kifunensine (KIF-JRFL) but did not neutralize wild-type tier 2 JRFL pseudoviruses ([Figure 2A](#F2){ref-type="fig"}), which is similar to the neutralization signature of V3-glycan bnAb precursors ([@R5]; [@R17]; [@R115]). V3-glycan types of bnAbs make contact with the highly conserved GDIR motif (Gly324, Asp325, Ile326, and Arg327) at the base of the V3 loop ([@R45]; [@R102]; [@R127]) and KIF-JRFL neutralization was abrogated or decreased in all neonate and adult macaque plasmas by the G324A mutation (ADIR) mutation ([Figure 2A](#F2){ref-type="fig"}). Mutating Asp325 and Arg327 in tandem (GAIA) ablated the plasma neutralization of KIF-JRFL in gp120-immunized adults, and as well, in a subset of the SOSIP immunized neonates and adult macaques ([Figure 2A](#F2){ref-type="fig"}). However, KIF-JRFL neutralization was not ablated when Asp325 or Arg327 were mutated individually ([Figure 2A](#F2){ref-type="fig"}).

Since non-neutralizing functional activity of antibodies is involved in protection against HIV-1 infection ([@R56]; [@R9]), we also compared Fc receptor (FcR)-dependent effector functions of plasma antibodies between neonatal and adult macaques after vaccination, including anti-body-dependent cellular phagocytosis (ADCP), which has been correlated with protection in previous preclinical studies ([@R8]; [@R131]), as well as the presence of plasma antibodies capable of binding to HIV-1 CH505-infected cells as an additional correlate of protection ([@R18]). SOSIP immunization of neonates in combined studies 2 and 3 had higher ADCP responses to CH505 T/F SOSIP across all time points compared to adult macaques (neonate versus adult p = 0.002, nonparametric longitudinal data analysis), whereas the ADCP responses to gp120 were similar between neonatal and adult macaques (neonate versus adult p = 0.15, nonparametric longitudinal data analysis) ([Figure 2B](#F2){ref-type="fig"}). Plasma antibody binding to the surface of CH505-virus-infected CD4^+^ T cells increased more rapidly in CH505-SOSIP-immunized neonatal macaques than adult macaques based on the group-by-time interaction (p = 0.038, nonparametric longitudinal data analysis) ([Figure 2C](#F2){ref-type="fig"}).

We have previously described several HIV-1 bnAbs with autoreactive profiles ([@R55]). We tested adult and neonatal plasma binding to autoantigens ([@R54], [@R55]) before and after immunizations. One adult macaque after gp120 immunization (week 59, animal 5,363) was found to be positive for dsDNA antibodies, whereas plasma from all the other adult or neonate macaques was negative (data not shown).

Neonatal and Adult Immune Cells Have Distinct Transcriptomes after HIV-1 Env Immunization {#S4}
-----------------------------------------------------------------------------------------

Next, we investigated transcriptome differences between neonatal (N = 3) and adult (N = 3) study 2 macaque peripheral blood mononuclear cells (PBMCs) at single-cell resolution after two immunizations (week 9) with CH505 SOSIP trimers using single-cell RNA sequencing (scRNA-seq) ([@R19]; [@R156]). We studied the week 9 time point after two immunizations, because this is the earliest time point when the antibody titers increased to near-peak titers and neonates and adult monkeys started to show differences in Env-binding titers. After filtering low-quality cells, we determined the transcriptomes of 23,040 neonatal and 29,266 adult cells with an average of 56,313 reads per cell and detected a median of 717 genes per cell. Single cells were clustered using graph-based clustering and visualized in two dimensions based on similarity of their transcriptional profiles by an unsupervised machine learning algorithm t-distributed stochastic neighbor embedding (tSNE) ([Figure 3A](#F3){ref-type="fig"}). Cell types that are associated with clusters determined by tSNE were identified using expression of transcript markers enriched in T cells (*CD3D*), B cells (*CD19*, *CD20*), NK cells (*NCR1*), and monocytes (*CD14, LYZ*) ([Figures 3B](#F3){ref-type="fig"} and [S2](#SD1){ref-type="supplementary-material"}). Using this approach, we found that immune cell subsets in PBMCs from neonatal macaques clustered together and distinct from the immune cell subsets from the adult macaques.

We determined differentially expressed (DE) transcripts using a likelihood ratio test ([@R84]) for neonatal immune cells compared to adults (all subsets \[ALL\] combined, 277 DE genes; [Table S1](#SD3){ref-type="supplementary-material"}), B cells (360 DE genes; [Table S2](#SD4){ref-type="supplementary-material"}), T cells (300 DE genes; [Table S3](#SD5){ref-type="supplementary-material"}), NK cells (428 DE genes; [Table S4](#SD6){ref-type="supplementary-material"}), and monocytes (623 DE genes; [Table S5](#SD7){ref-type="supplementary-material"}). We found that 97 DE transcripts were common in all four neonatal immune cell subsets with 68, 42, 113, and 318 DE transcripts unique to B, T, NK, and monocyte cell populations, respectively ([Figure 3C](#F3){ref-type="fig"}). The 97 DE transcripts common in all four neonatal immune cell subsets were enriched for genes involved in the actin cytoskeleton (*ACTB*) ([Figures 3D](#F3){ref-type="fig"} and [3E](#F3){ref-type="fig"}) and cell movement, RNA splicing, and other immune functions, such as interferon response (*IFITM1* and *IRF3*) ([Figures 3D](#F3){ref-type="fig"} and [3E](#F3){ref-type="fig"}), suggesting that these transcripts are hallmarks of neonatal immunity in T, B, and NK cells and monocytes.

DE genes related to immune tolerance (*BCL2*, *CD22*, *CD40*, *CD72*, *IL10RA*, *CD86*, *PIK3R1*, *PRKACA*, *TNFSF13*, *IL2RB*, and *TGFB1*) in different cell subsets were also identified ([Table S6](#SD8){ref-type="supplementary-material"}). Notably, *BLC2* that encodes an integral anti-apoptotic protein in lymphocytes was upregulated and the transcript that encodes *IL10RA* was downregulated in neonatal lymphocytes compared to adult macaque T, B, and NK cells and monocytes ([Figure 3E](#F3){ref-type="fig"}; [Table S6](#SD8){ref-type="supplementary-material"}). This supports the hypothesis of decreased regulation of immune cell apoptosis in Env-induced neonate immune responses compared to adult macaques. Overall, these data raise the hypothesis that neonatal immune cells were more primed for activation, cellular trafficking, and decreased apoptosis in the context of immune responses.

Neonate B Cells Had Upregulated Marginal Zone (MZ) and Lymphocyte Activation Transcripts {#S5}
----------------------------------------------------------------------------------------

In PBMCs, neonatal and adult macaque B cells that expressed CD19 (*CD19*) and/or CD20 (*MS4A1*) transcripts were re-interrogated by performing tSNE unsupervised clustering to identify differences in study 2 neonate and adult B cells after two immunizations (week 9) ([Figure 4A](#F4){ref-type="fig"}). This resulted in 5,131 and 3,910 neonate and adult B cells, respectively, that clustered in two distinct groups based on their cellular transcriptomes. The 68 DE transcripts unique to B cells included 55 upregulated and 13 downregulated transcripts in neonatal B cells that did not overlap with other immune cell subsets ([Figure 4A](#F4){ref-type="fig"}; [Table S2](#SD4){ref-type="supplementary-material"}). Transcripts upregulated in neonatal B cells were associated with B cell receptor activation and proliferation and antigen presentation, suggesting a more activated state of B cells in neonates ([Figure 4B](#F4){ref-type="fig"}). Examples of markers that have been associated with B cell activation that are upregulated in macaque neonatal B cells are *CD79B,* which is critical for B cell receptor (BCR) signaling ([@R23]; [@R26]; [@R57]); *FCRL1* ([@R28]; [@R68]) and *CD40* ([@R38]; [@R48]), which are critical for T-cell-dependent B cell activation; and *MAP3K8,* a kinase critical for transducing the CD40 signal within B cells ([@R39]) ([Figure 4C](#F4){ref-type="fig"}). Interestingly, neonatal B cells after vaccination also upregulated transcripts associated with naive/MZ B cells (*IGHM*, *CD1C*, *CD22*, and *BTLA*) ([@R33]; [@R139]), consistent with previous reports of increased expression of IgM and CD1c on MZ B cells in early childhood ([@R118]; [@R31]; [@R138]; [@R140]) ([Figure 4D](#F4){ref-type="fig"}). In addition to activating B cell markers, we identified inhibitors of B cell activation (*CD72*, *SH3BP5*, and *NCOR1*) ([@R3]; [@R128]; [@R153]) upregulated in neonate versus adult B cells, suggesting induction of groups of neonatal B cell transcripts that can either activate or inhibit B cell responses ([Figure 4E](#F4){ref-type="fig"}). CD20 and the chemokine receptor CXCR4 are critical for B cell trafficking and are molecular targets for cancer immunotherapies ([@R12]; [@R97]; [@R107]; [@R130]). Interestingly, in both neonatal and adult macaques, the expression of the CD20 transcript *MS4A1* and the *CXCR4* transcript were expressed with little overlap or co-expression within the same B cell ([Figure 4F](#F4){ref-type="fig"}), suggesting possible interactions between CD20 and CXCR4 ([@R12]; [@R107]).

Frequency of B Cell Subsets in Peripheral Blood of Immunized Neonatal and Adult Macaques {#S6}
----------------------------------------------------------------------------------------

We next compared B cell subsets in neonatal and adult macaques immunized with CH505 SOSIPs in studies 2 and 3. PBMCs collected 2 weeks after the first, third, and sixth immunizations were analyzed by flow cytometry for B cell subpopulations. We used the tSNE dimensional reduction algorithm to visualize and analyze multiple B cell populations in two-dimensional plots ([Figures 5](#F5){ref-type="fig"} and [S3](#SD1){ref-type="supplementary-material"}; [@R24]). We identified eight B cell subsets among CD20^+^CD3^−^ CD14^−^ CD16^−^ lymphocytes: naive, IgM^+^ memory, IgG^+^ memory, IgM^−^ IgG^−^ memory, IgM^+^ plasmablasts, IgM^−^ plasmablasts, MZ-like, and a rare population of undefined B cells characterized by expression of Ki67, CD1c, CD27, and high levels of IgM ([Figure 5](#F5){ref-type="fig"}, Query 1). Across all time points post-vaccination, neonatal macaques had higher frequencies of naive B cells (neonate versus adult p = 0.007) and lower frequencies of IgG^+^ memory B cells (neonate versus adult p = 0.0005) and IgM^−^ IgG^−^ memory B cells (neonate versus adult, p = 0.0002) than adults, while frequencies of IgM^+^ memory B cells were comparable between neonates and adult macaques (neonate versus adult p = 0.69) ([Figure 5](#F5){ref-type="fig"}). IgM^+^ and IgM^−^ plasmablast frequencies were higher in adults than in neonates across all time points (neonate versus adult p = 0.027 for IgM^+^ plasmablast; p = 0.04 for IgM plasmablast) ([Figure 5](#F5){ref-type="fig"}). However, neonates showed a higher frequency of B cells expressing a MZ-like phenotype (CD20^+^IgM^+^CD38^+^CD1c^+^CD27^−^ CD21^+^IgG^−^) (neonate versus adult p = 0.00009) ([Figure 5](#F5){ref-type="fig"}) as well as more "Query 1" (Ki67^+^CD1c^+^CD27^+^IgM^2+^) B cells (neonate versus adult p = 0.0007) across all time points ([Figure 5](#F5){ref-type="fig"}). These statistical assessments for [Figure 5](#F5){ref-type="fig"} were conducted using nonparametric longitudinal data analysis (see [STAR Methods](#S11){ref-type="sec"}).

Increased Frequencies of Activated Blood Tfh Cells in Neonatal Macaques Compared to Adult Macaques {#S7}
--------------------------------------------------------------------------------------------------

In addition to B cells, we studied T cell subsets in PBMCs by flow cytometry in studies 2 and 3 in animals immunized with SOSIP trimers ([Figures 6](#F6){ref-type="fig"} and [S3](#SD1){ref-type="supplementary-material"}). Across all time points, based on nonparametric longitudinal data analysis (see [STAR Methods](#S11){ref-type="sec"}), neonatal macaques had higher frequency of total CD4^+^ T cells (neonate versus adult p = 0.017) and naive CD4^+^ T cells (neonate versus adult p = 0.002) but lower frequencies of CD8^+^ T cells (neonate versus adult p = 0.016), effector memory CD4^+^ T cells (neonate versus adult p = 0.006), and effector memory CD8^+^ T cells (neonate versus adult p = 0.005) than adult macaques ([Figure 6](#F6){ref-type="fig"}), consistent with the findings of different T lymphocyte subsets in human neonates and adults ([@R117]; [@R122]). The frequencies of naive CD8^+^ T cells, central memory CD4^+^ T cells, central memory CD8^+^ T cells, and regulatory T (Treg) cells were not significantly different, which is also consistent with the findings in humans ([@R117]). T follicular helper-like (Tfh) cells are required for the survival and selection of B cells within germinal centers in lymphoid tissues, and a circulating counterpart (circulating Tfh \[cTfh\] cells) has been implicated as an indicator of Tfh cell activity in tissues ([@R1]; [@R77]). The frequency of PD1^+^CXCR5^+^ cTfh cells within CD4^+^ T cells was not significantly different between neonatal and adult macaques across all time points ([Figure 6](#F6){ref-type="fig"}). cTfh cells were further characterized by analyzing the Tfh cell markers inducible T cell costimulator (ICOS), Ki67, and CD69. The frequency of activated cTfh cells (ICOS^hi^Ki67^+^ or ICOS^hi^CD69^+^) within cTfh cells was increased across all time points in neonates compared with adults based on nonparametric longitudinal data analysis (neonate versus adult p = 0.003 for ICOS^hi^Ki67^+^; neonate versus adult p = 0.002 for ICOS^hi^CD69^+^) ([Figure 6](#F6){ref-type="fig"}).

Transcriptional Differences in T Cells and Monocytes in Neonate and Adult Blood {#S8}
-------------------------------------------------------------------------------

Since we observed differences between the frequency of neonatal and adult macaque activated T cell subsets in the context of gp140 SOSIP immunization, we next studied the transcriptome of T cells in neonatal and adult macaques from study 2 after two immunizations ([Figure S4A](#SD1){ref-type="supplementary-material"}). T cells (*CD3D* expressing) of neonatal and adult macaques formed distinct clusters based on their cellular transcriptomes ([Figure S4A](#SD1){ref-type="supplementary-material"}). Unsupervised clustering identified 19 (T0--T18) distinct T cell transcriptional clusters ([Figures S4A](#SD1){ref-type="supplementary-material"} and [S4B](#SD1){ref-type="supplementary-material"}). 42 transcripts that were uniquely DE in neonatal and adult T cells were identified ([Figure 3](#F3){ref-type="fig"}; [Table S3](#SD5){ref-type="supplementary-material"}). For example, neonatal T cells upregulated integrin, adhesion encoding transcripts (*ITGB7*, *ICAM3*, and *ITGA6*), and the transcription factor *LEF1* ([@R150]) but had lower expression of the transcription factors *ETS1* and *AHI1* ([@R61]; [@R92]; [Figures S4C](#SD1){ref-type="supplementary-material"} and [S4D](#SD1){ref-type="supplementary-material"}).

Additionally, neonatal and adult blood monocytes (*CD14*, *LYZ* expressing) from study 2 clustered distinctly, but monocytes from individual neonatal and adult macaques also exhibited distinct transcriptomes, indicating high levels of individual transcriptional heterogeneity ([Figure S5A](#SD1){ref-type="supplementary-material"}). Unsupervised graph-based clustering identified seven distinct monocyte transcriptional clusters (M0--M6) ([Figures S5A](#SD1){ref-type="supplementary-material"} and [S5B](#SD1){ref-type="supplementary-material"}). Overall, we identified 318 transcripts that were DE in neonatal monocytes compared to adult monocytes ([Figure 3](#F3){ref-type="fig"}; [Table S5](#SD7){ref-type="supplementary-material"}), such as RNAase (*RNASE6*), the RNA editor *APOBEC3A* ([@R10]; [@R109]; [@R121]), the innate inflammatory molecule allograft inflammatory factor-1 (*AIF1*), and the damage-associated membrane protein (DAMP) *S100A8* ([@R93]; [@R99]; [@R110]; [@R154]), that were upregulated in neonatal monocytes ([Figures S5C](#SD1){ref-type="supplementary-material"} and [S5D](#SD1){ref-type="supplementary-material"}).

To confirm differential transcriptome expression in neonatal and adult macaque immune cells, we performed scRNA-seq on 7,814 PBMCs from a neonatal macaque and 6,464 cells from an adult macaque in gp140 SOSIP immunization study 3 after the second immunization (week 6). We found that stabilized SOSIP-immunized neonatal and adult macaques had similar clustering patterns among all cell types as observed in single cells from macaques immunized with CH505 SOSIPs in study 2 ([Figures S6A](#SD1){ref-type="supplementary-material"}--[S6C](#SD1){ref-type="supplementary-material"}; [Tables S7](#SD9){ref-type="supplementary-material"} and [S8](#SD10){ref-type="supplementary-material"}). Moreover, neonatal B cells had similar upregulation of transcripts associated with B cell activation ([Figure S6D](#SD1){ref-type="supplementary-material"}), naive and MZ-like B cells ([Figure S6E](#SD1){ref-type="supplementary-material"}), and B cell inhibitory molecules ([Figure S6F](#SD1){ref-type="supplementary-material"}), as observed in CH505-SOSIP-immunized neonates in study 2 ([Figure 4](#F4){ref-type="fig"}). Thus, in two cohorts of neonates and adults immunized with SOSIP trimers, we found similar transcriptional program differences between neonatal and adult macaques.

Bacterial Composition of Fecal Microbiota in Neonatal and Adult Macaques {#S9}
------------------------------------------------------------------------

Since the gut microbiome can influence antibody responses to HIV-1 Env ([@R50]; [@R146], [@R148]), we wondered whether the gut microbiome could be one factor that shaped the neonatal and adult Env immune responses. Thus, we compared the microbiome of CH505-SOSIP-immunized neonatal macaques in study 2, dams (moms), and unrelated adult macaques by 16S ribosomal RNA (rRNA) analysis on fecal samples over time during vaccination. Colonization of the microbiome occurred early within the first week of life in neonatal macaques ([Figure 7A](#F7){ref-type="fig"}). The most abundant phyla in the fecal samples of adult, dam, and neonatal macaques were Firmicutes and Bacteroidetes ([Figure 7A](#F7){ref-type="fig"}), consistent with previous findings in macaques ([@R50]; [@R88]). On the genus level, the compositions of fecal microbiota in neonatal macaques were dynamic at early time points (\<9 weeks) and became similar to adults and dams at later time points ([Figure 7A](#F7){ref-type="fig"}). Rarefaction curves generated for the phylogenetic distance showed that the fecal microbiota of adult macaques and dams demonstrated greater diversity than those of neonatal macaques ([Figure 7B](#F7){ref-type="fig"}). Thus, the composition of neonatal fecal microbiota was dynamic at early time points and underwent changes toward a composition similar to adult macaques. These data also raised the hypothesis that early development of the microbiome as soon as within 1 week of life may imprint neonatal B cell immunity to similarly respond to HIV-1 Envs like adults and are consistent with previous studies that suggested B cell imprinting by the microbiota soon after birth ([@R96]; [@R141]).

DISCUSSION {#S10}
==========

In this study, we have demonstrated that the neonatal immune system in rhesus macaques is capable of responding to HIV-1 Env gp120 monomer or SOSIP trimer immunogens and can generate levels of plasma Env-binding antibodies similar to adult macaques. Neonatal and adult macaques also elicited similar quality of plasma neutralizing antibodies and blood-derived B cell repertoires that responded to the HIV-1 Env immunogens. Neonatal macaques had a distinct transcriptome profile of increased *BCL2* in T cells and decreased *IL10RA* transcripts in T, B, and NK cells and monocytes of post-vaccination immune cells compared to adult macaques. Moreover, neonatal macaques had a higher frequency of activated cTfh T cells across all time points compared with adults.

The hepatitis B surface antigen vaccine induced higher antibody responses in human newborns than in adults ([@R100]), whereas the diphtheria, pertussis, and tetanus vaccine induced lower concentrations of antibodies in young infants ([@R124]). Here, we show that both CH505 sequential gp120 and gp140 SOSIP Envs elicited comparable antibody responses in neonatal and adult macaques.

Given the structural properties and poly-reactivity of some HIV-1 Env-reactive antibodies, including bnAbs ([@R55]; [@R90]), immune tolerance controls have been reported to limit the development of neutralizing antibodies (NAbs) ([@R53]; [@R62]). Recent reports indicate that babies can make HIV-1 Env bnAbs at a higher frequency than adults and do so faster than adults as observed within 1 year of infection ([@R47]; [@R91]), which may indicate a more permissive immune environment of the development of HIV-1 bnAbs. Single-cell transcriptomic analysis of neonatal versus adult blood immune cells showed elevated transcripts that encoded the apoptosis regulatory BCL2 (*BCL2)* in neonatal T cells and decreased *IL10RA* transcripts in neonatal T, B, and NK cells and monocytes, suggesting that the developing infant immune system may have less stringent immune controls of HIV-1 Env-reactive antibodies. While neonatal B cells have upregulation of transcripts associated with naive lymphocytes and inhibitory molecules, neonatal B cells also expressed higher levels of activation markers, suggesting a lower B cell activation threshold than adult B cells. Additional factors related to vaccination regimens may also be important for bnAb induction even in a more permissive immune system. It remains to be determined how the transcriptome of neonate immune cells changes due to HIV-1 Env vaccine regimens, because we were unable to obtain pre-vaccination samples for transcriptome analysis in neonates. We speculate that the transcriptome differences in post-vaccination immune cells in neonatal and adult macaques may be due to intrinsic differences in neonatal and adult immune systems, including the cell subsets that are capable of responding to HIV-1 Env vaccines. Previous studies have suggested that neonates may have specific immune cell subsets and features that are different than adults, but they contribute similarly to HIV-1 Env immunity ([@R4]; [@R82]). Here, we studied the transcriptome of total PBMCs in a small sample size. Thus, additional pre-and post-vaccination transcriptome studies of neonate and adult macaques may be more informative for defining immune cell subsets that directly impact humoral HIV-1 Env immunity.

While neonates have a transcriptional pattern suggestive of more hyperreactive B cells, immunization of neonates with either sequential gp120s or SOSIP trimers did not induce tier 2 autologous or heterologous neutralizing antibodies. It is not clear why no autologous neutralizing antibodies were seen in these studies, since stabilized CH505 transmitted/founder SOSIP trimers have induced tier 2 autologous NAbs in rabbits and sequential CH505 gp140s have induced autologous and heterologous neutralizing antibodies in select macaques ([@R114]). Adjuvants may impact neonatal immunity to vaccines ([@R135]; [@R69]; [@R83]). The TLR4 agonist GLA/SE or TLR3 agonist poly-ICLC ([@R6]; [@R11]; [@R25]; [@R80]; [@R137]) elicited comparable antibody responses in neonates compared to adults in response to HIV-1 Env forms. Recently, it was discovered that TLR7/8 adjuvant improves the neonatal antibody response to pneumococcal vaccines ([@R37]) and may improve HIV neutralizing antibody responses. In addition, our study suggests that the immunogens used for these studies are not optimized to promote the full maturation of bnAb B cell lineages, even in the setting of neonatal immunization. Thus, bnAbs were not induced, indicating the need for more specifically designed sequential Envs to overcome additional limitations on induction of bnAbs, including the development of Envs to select for improbable mutations that are common in bnAb B cell lineages ([@R147]; [@R17]; [@R143]). Additionally, vaccine delivery platforms can impact neonatal immunity; replication-deficient viral vectors have been shown to elicit significantly higher antibody responses in human infants under 2 years compared with adults ([@R14]), and the DNA measles vaccine induced significantly higher plaque reduction neutralization titers in neonatal mice compared with adults ([@R22]). In our studies, both DNA prime with protein boost and protein alone elicited comparable neonatal HIV-1 Env responses.

Neonatal B cells had higher gene expression levels of MZ-like B cell markers compared to adults, suggesting that this B cell pool may contribute to HIV-1 Env B cell immunity in neonates. HIV Env-specific B cells in adults and neonates exhibited IgG or IgM memory phenotype after the third and sixth immunizations. MZ-like B cells could be one of the precursors of these IgG or IgM memory B cells. This may be particularly important for HIV-1 vaccine development, since some broadly neutralizing anti-HIV-1 Env antibodies may be derived from MZ B cells that produce polyspecific autoantibodies and are subject to host tolerance control mechanisms ([@R15]; [@R54], [@R55]).

Finally, the microbiome profiles in neonatal and adult macaques were studied, and we found that neonates were colonized soon after birth, indicating that microbial imprinting of the B cell repertoire ([@R141]) can occur within 1 week of birth. We previously showed that the intestinal microbiome influences vaccine-induced antibody responses ([@R50]; [@R146]), but associations between specific microbial taxa and the quality of vaccine-induced antibody responses in neonates remains to be determined.

In summary, our studies suggest human neonates will be able to respond as well as adults to Env immunogens and may benefit from early immunization prior to sexual debut. Moreover, this study provides an initial insight into the transcriptome profile of neonate and adult macaques following HIV-1 vaccination. Future transcriptomic studies may expand on these approaches by studying specific immune cell subsets in a larger number of animals to define neonatal and adult immune cell subsets and their properties that may contribute to humoral responses to vaccines or pathogens.

STAR★METHODS {#S11}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S12}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Barton F. Haynes (<barton.haynes@duke.edu>). This study did not generate new unique reagents. There are no restrictions to the availability of data generated in this study.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S13}
--------------------------------------

All rhesus macaques (*Macaca mulatta*) were housed indoors at the California National Primate Research Center (CNPRC), CA or Bioqual, Rockville, MD, and were maintained in accordance with the Association for Assessment and Accreditation of Laboratory Animals with the approval of the Animal Care and Use Committees of the UC Davis. Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication, 2011 edition. The neonatal macaques were dam-reared, and were up to 7 days of age at the time of the first immunization. Dam-reared neonatal macaques were selected because it is most natural, and because it was previously shown that nursery-reared neonatal macaques have differences in microbiome and immune function ([@R7]; [@R94]). Study approval: All animal experiments performed in this study were approved by the Duke, University of California, Davis and Bioqual IACUCs. The term neonatal macaques was used to denote macaques that received their initial immunizations beginning from birth to one week of life.

### Vaccine Regimens and Study Groups {#S14}

CH505 transmitted-founder (T/F), week53, week78 and week100 gp120 Env-variants were administered in sequential combinations in GLA/SE (IDRI) in 4 neonatal macaques \[2 females (45405 and 45423) and 2 males (45404 and 45425)\] and 4 adult macaques (all males) for a total of 8 and 6 immunizations, respectively, in Study no. 1. CH505 T/F (3 times), week53, week78 and week100 sequential CH505 gp140 SOSIPs were administered in sequential combinations in GLA/SE in 3 neonatal macaques \[2 females (179059 and 178951) and 1 male (177890)\] and 4 adult macaques \[3 females (150799, T270, T274) and 1 male (150129)\] for a total of 6 immunizations in Study no. 2. CH505 T/F gp145 DNA (2 times) and CH505 T/F, week53, week78 and week100 sequential CH505 gp140 v4.1 SOSIP were administered in sequential combinations in Poly ICLC (Hiltonol, Oncovir) in 2 neonatal macaques \[1 female (177715) and 1 male (178122)\] and 4 adult macaques \[3 females (T241, T243, 177850) and 1 male (177811)\] for a total of 6 immunizations in Study no. 3. Stabilized CH505 SOSIPs contained E64K and A316W trimer stabilization mutations ([@R114]; [@R29]).

Immunizations were administered intramuscular in the leg of each animal with a total of 50μg (neonatal macaques) or 100 μg (adult macaques) of total CH505 proteins. When necessary, adult animals were immobilized with ketamine HCl (10 mg/kg) administered intramuscularly; when feasible, neonatal macaques were handheld for the procedures and sample collections. Blood samples were collected via venipuncture at 2 weeks after each immunization. Stool was collected from the cage pan, or from the neonate when it was handheld. Vaccine-induced Ab repertoires were studied 2 weeks after 4^th^ and 6^th^ immunizations in plasma and blood-derived memory B cells of four neonatal macaques immunized with CH505 gp120s.

METHOD DETAILS {#S15}
--------------

### Flow Cytometry Memory B Cell Sorting {#S16}

B cell sorting was performed using flow cytometry approaches as described ([@R144]; [@R155]). Briefly, peripheral blood mononuclear cells (PBMCs) of immunized macaques were stained with AquaVital dye, CD14 (BV570), CD16 (PE-Cy7), CD3 (PerCP Cy5.5), CD20 (FITC), CD27 (APC-Cy7), and IgD (PE). Single-cell isolation of memory B cells (AquaVital dye^−^, CD14^−^, CD16^−^, CD3^−^, IgD^−^, CD20^+^) stained with both AlexaFluor 647 and Brilliant Violet 421--tagged HIV-1 CH505 T/F gp120 proteins (CH505 double positives), and cells stained with BV421-tagged CH505 T/F gp120, but not AF647-tagged CH505 T/F gp120 Δ371 mutant protein (CH505 single positives) was performed using a fluorescence-activated cell sorter FACSAria II (BD Biosciences, San Jose, CA), and the flow cytometry data were analyzed using FlowJo (Treestar, Ashland, OR).

### Phenotypic Analysis by Flow Cytometry {#S17}

Macaque PBMCs were stained by a panel of markers, including CD38, Bcl-6, CD1c, CD69, CD21, Ki67, IgG, IgM, CD3/CD14/CD16, CD27, and CD20 to discriminate various B cell subsets. B cells (AquaVital dye^−^, CD14^−^, CD16^−^, CD3^−^, CD20^+^) stained with both AlexaFluor 647 and Brilliant Violet 421-tagged HIV-1 CH505 T/F gp120 proteins or CH505 T/F stabilized SOSIP proteins were defined as gp120-specific or SOSIP-specific B cells. For the T cell subsets, a panel of markers including ICOS, CCR6, Bcl-6, CD183, CD69, CD185, Foxp3, Ki-67, CD3, PD-1, CD8a, CCR7, CD25, CD4 and CD45RA was used. Aqua Vital Dye was used to distinguish live from dead cells (Invitrogen).

### Ab Binding Specificities and Epitope Mapping {#S18}

Plasma Abs and recombinant mAbs were screened for binding specificities to multiclade HIV-1 Envs by means of standard ELISA as described ([@R132]). We isolated candidate CD4bs mAbs and non-CD4bs mAbs as previously described ([@R149]). Plasma Abs were tested for epitope specificity by peptide microarray as described ([@R123]; [@R133]). Linear peptides (15-mers overlap by 12) from vaccine-strain and consensus Env gp120 was used in this analysis. Additionally, we mapped Ab epitope for plasma and blood-derived mAbs via competitive inhibition assay in ELISA ([@R155]). For CD4 (binding site) blocking assays we used soluble CD4 (Progenics Pharm Inc.) or CH106 bnAb. CH65, HA influenza antibody, was used as a negative control binding antibody.

### Antibody-Dependent Cellular Phagocytosis Assay {#S19}

Antibody-dependent phagocytosis was assessed by the measurement of the uptake of antibody-opsonized, antigen-coated fluorescent beads by the monocytic THP-1 cell line (ATCC; \#TIB-202) ([@R2]; [@R129]).

### Plasma Binding to the Surface of HIV-1-Infected Cells {#S20}

Indirect surface staining was used to measure the ability of NHP plasma samples to bind HIV-1 envelope expressed on the surface of infected cells as described ([@R18]; [@R40]). CD4+ T cells (CEM.NKR.CCR5) infected with HIV-1 CH505TF was used as the effector cells ([@R58]; [@R79]; [@R134]).

### Neutralization Assays {#S21}

Neutralization activity of Abs was measured in 96-well culture plates by using Tat-regulated luciferase (Luc) reporter gene expression to quantify reductions in virus infection in TZM-bl cells ([@R112]). Wild-type JR-FL and GDIR alanine mutant JR-FL viruses were produced in kifunensine-treated cells ([@R115]). HIV-1 B.JR-FL produced in the presence of kifunensine (KIF-JRFL), a glycosylation pathway inhibitor that results in a high density of Man~9~GlcNAc~2~ glycans was previously described ([@R35]; [@R116]). For plasma tested in neutralization, the starting dilutions for neonatal macaques 177890, 178951 and 179059 were 1:100, 1:50 and 1:100 due to limited samples; all other samples were tested at starting dilution of 1:20. Neutralization sensitivity of HIV-1 strains: easy-to-neutralize (tier 1) and difficult-to-neutralize (tier 2).

### PCR Isolation of Heavy and Light Chain Genes {#S22}

Heavy (IGHV) and light (IGKV, IGLV) chain genes were amplified as described previously ([@R70]). The PCR-amplified genes were then purified and sequenced with 4 mM of forward and reverse primers. Sequences were analyzed by using the macaque library in Clonalyst, such as the VDJ arrangements of the immunoglobulin IGHV, IGKV, and IGLV sequences, somatic mutations, and CDR3 length ([@R63]; [@R144]). Sequences were subject to statistical analysis for lineage membership as described ([@R146]).

### Transient and Recombinant Ab Expression {#S23}

Transient and recombinant Ab expressions were performed as described ([@R70], [@R74]; [@R144]). Briefly, an aliquot of the purified PCR amplicon was used for overlapping PCR to generate a linear expression cassette. The expression cassette was transfected with ExpiFectamine (Thermo Fisher Scientific) into 293T cells. The supernatant containing recombinant Abs were used for binding assays. The genes of selected heavy chains and kappa/lambda chains were synthesized as IgG1 and cloned into pcDNA3.1 plasmid (GenScript). Recombinant Ab expressions and purification were performed as described ([@R74]; [@R144]).

### Single-Cell RNA Sequencing of Rhesus Macaque PBMCs {#S24}

PBMCs from neonatal and adult macaques (macaque 150129 not included) immunized with CH505 SOSIPs in **Study no.2** at week 9 (post 2 immunizations) were used. We also studied PBMCs from one neonatal macaque (177715) and one adult macaque (T243) from **Study no. 3** at week 6 (post 2 immunizations). PBMCs were thawed, washed and placed in single-cell suspensions with PBS + 0.04% BSA. Cellular suspensions were loaded on a GemCode Single-Cell instrument (10X Genomics, Pleasanton, CA) to generate single-cell beads in emulsion ([@R156]). Single-cell RNA-seq libraries were then prepared using a GemCode Single Cell 3^′^ Gel bead and library kit (10X Genomics). Single-cell barcoded cDNA libraries were quantified by quantitative PCR (Kappa Biosystems, Wilmington, MA) and sequenced on an Illumina NextSeq 500 (San Diego CA). Read lengths were 26 bp for read 1, 8 bp i7 index, and 98 bp read 2. Cells were sequenced to greater than 50,000 reads per cell. The Cell Ranger Single Cell Software Suite was used to perform sample de-multiplexing, barcode processing and single-cell 3^′^ gene counting ([@R156]). Reads were aligned to macaque genome assembly, Mmul_8.0.1. from the Ensemble ([http://ensemble.org](http://ensemble.org/)) ([@R34]; [@R156]). We could not identify high expression of CD4 transcript in T cells, which may indicate disparate expression of the transcript and surface protein or polymorphisms in the CD4 transcript that hinder alignment of transcript reads to the genome reference. Graph based cell clustering, dimensionality reduction and data visualization were analyzed by the Seurat R package ([@R113]). Cells that exhibited high transcript counts, \> 0.1% mitochondrial transcripts were excluded from analysis. Differentially expressed transcripts were determined in the Seurat R package utilizing the Likelihood-ratio test for single cell gene expression statistical test ([@R84]). Graphics were generated using the Seurat and ggplot2 R packages. Four known cell types were identified within PBMCs on the tSNE plot representation by expression of markers used to define the clusters -- CD19 and/or CD20, B cells; CD3D, T cells; NCR1, NK cells; LYZ and CD14, Monocytes.

### Microbiome Analysis {#S25}

The V4 region of the 16S gene was amplified with primers 515FB/806RB following protocols of the Illumina 16S amplicon protocols of the Earth Microbiome Project (<http://press.igsb.anl.gov/earthmicrobiome/protocols-and-standards/16s/>). Sequencing was performed using 150 bp paired end Illumina MiSeq sequencing. The obtained 16,318,607 paired reads were merged with fastqjoin \[1\], yielding 13,727,040 assembled 16S amplicon sequences. Subsequent quality filtering and demultiplexing was performed with split_libraries_fastq.py of QIIME v. 1.9.1 ([@R21]), setting a minimal Phred quality score of 20. These settings resulted into 12,549,251 filtered amplicons, with a median length of 253 bp, which were used for downstream analysis. During further processing with vsearch v. 1.11.1 ([@R108]), amplicon sequences were dereplicated, filtered for chimeras, and clustered at a 97% identity threshold into 89,268 operational taxonomic units (OTUs). Subsequent taxonomic assignment against the 16S reference sequence set of SILVA, v. 1.28 ([@R106]), OTU sequence alignment and generation of an unrooted phylogenetic tree, was performed in QIIME. A basic statistical diversity analysis was performed, using core_diversity_analysis.py of QIIME, including alpha-, beta-diversity, and relative taxa abundances in sample groups. The determined relative taxa abundances were further analyzes with LEfSe (Linear discriminant analysis effect size) ([@R119]), to identify differential biomarkers in sample groups. Alpha diversity analysis was performed on samples after rarefaction to 10000 sequences/sample (minimum sampling depth). Rarefaction curves were generated for the phylogenetic distance between two groups. Phylogenetic distance were calculated at a rarefaction depth of 10000 sequences per sample.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S26}
---------------------------------------

Exact Wilcoxon test was performed to compare differences in mAbs from neonatal and adult macaques with p value \< 0.05 considered significant. Likelihood ratio test was performed to analyze the differentially expressed transcripts with p value \< 0.05 considered significant. Nonparametric analyses of longitudinal data (R package nparLD) were performed to test the hypothesis that there exist differences between groups across time (p value \< 0.05 considered significant) ([@R98]). This method was used to answer two questions for repeated-measures on the same subjects: 1) Are the age group effects similar over time/Are the age group profiles parallel?; 2) Do the groups have the same effect/Do the groups have coincident profiles? This statistical method does not require distributional assumptions and allows for the assessment of interaction terms even with a small sample size. Due to the small sample size within SOSIP immunized animals in **Studies nos. 2 and 3**, we could not conduct a stratified statistical analyses and thus combined these groups for comparisons.
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![Binding Antibody Responses and Repertoire Analysis of Neonatal and Adult Rhesus Macaques Immunized with CH505 Envs\
(A) The kinetics of plasma antibody binding to CH505 T/F gp120, stabilized CH505 T/F SOSIP, and MN gp41 in vaccinated neonatal (blue) and adult (red) rhesus macaques tested by ELISA. Each symbol represents one animal, and the best-fit line represents the mean among each group of animals per vaccine group. The immunogens were sequential CH505 gp120s (study 1), CH505 SOSIPs (study 2), and stabilized CH505 SOSIP Envs (study 3), with adjuvants listed below. PBMCs and plasma were collected at each vaccination and 2 weeks after each vaccination. The arrows represent the time of immunization and sequential immunogens (Transmitted/Founder-TF, week 53, week 78, and week 100) are listed below. Nonparametric analysis of longitudinal data (nparLD) was performed on SOSIP-immunized animals combined in studies 2 and 3 (group by time interaction, p = 0.038 for gp120 binding).\
(B) Frequency of CD4-binding site (CD4bs) mAbs in total CH505 Env-reactive Abs that were isolated from CH505-gp120s-immunized neonatal and adult rhesus macaques after the fourth immunization.\
(C) The IGHV nucleotide mutation frequency (%) and amino acid HCDR3 length of CD4bs mAbs, non-CD4bs mAbs, and HIV-1 Env nonreactive mAbs from CH505-gp120s-immunized neonatal (N = 4) and adult (N = 8) rhesus macaques in study 1 inferred by Cloanalyst software program. This analysis includes four additional adult macaques that recieved sequential CH505 Env vaccine regimens as previously reported ([@R147]). Each symbol represents one mAb, and the filled symbols (black) represent the mean mutation frequency and HCDR3 length for each rhesus macaque per study. Mean, 25th, and 75th percentile values are listed above the plot.\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1568955-f0001){#F1}

![Plasma Neutralizing and Non-neutralizing Functions of Neonatal and Adult Rhesus Macaques Immunized with CH505 Envs\
(A) Neutralization profile of plasma from vaccinated neonatal (blue) and adult (red) rhesus macaques via TZM-bl assay studied in each group after six immunizations. Neutralization key is shown on the right. Murine leukemia virus (MuLV) was used as negative virus control.\
(B) In CH505 gp140 SOSIPs immunization studies 2 and 3, phagocytosis of CH505 T/F gp120-coated or stabilized CH505 T/F SOSIP-coated beads by THP-1 cells using neonatal and adult macaque plasma before (after the first immunization for neonates due to limited pre-samples) and after the second and sixth immunizations. CH65 and HIVIG were used as negative and positive control antibodies, respectively. Bead phagocytosis was quantified using the phagocytosis score. Horizontal bars are the group mean (average of two replicate experiments).\
(C) Plasma titers of antibodies from neonatal and adult macaques that bound to the surface of the CH505-virus-infected CD4^+^ T (CEM.NKR.CCR5) cell line measured by flow cytometry before (after the first immunization for neonates due to limited pre-samples) and after the second and sixth immunizations. Horizontal bars are the group mean. nparLD was performed on SOSIP-immunized animals combined in studies 2 and 3 (p = 0.15 for CH505 T/F gp120 beads group and p = 0.002 for stabilized CH505 T/F SOSIP beads group in Figure 2B; p = 0.038 for group by time interaction in Figure 2C).\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1568955-f0002){#F2}

![scRNA-Seq of PBMCs of HIV-1 Env-Immunized Neonatal and Adult Rhesus Macaques\
(A) Two-dimensional plot from unsupervised clustering by t-distributed stochastic neighbor embedding (tSNE) of the single-cell transcriptomes from 52,306 PBMCs isolated from three neonate (blue) and three adult (red) rhesus macaques after CH505 SOSIPs immunization (week 9) in study 2.\
(B) B, T, NK, and monocyte cells were identified within PBMCs on tSNE plot representation by expression of cell surface markers.\
(C) Five-way Venn diagram of the differentially expressed genes (likelihood ratio test, p ≤ 0.05) in neonate and adult cells detected in all four cell types combined (ALL), B cells, T cells, NK cells, and monocytes.\
(D) Heatmap of representative transcripts that were changed in ALL populations. Panels represent individual macaques, and each pixel column is the expression of an individual cells. Transcripts are on the rows with the normalized expression (*Z* scores) colored by the legend (red, more upregulated; blue, more down-regulated). Genes with human orthologs are labeled and colored by known functional ontology (actin cytoskeleton and cell movement, red; RNA splicing, blue; other immune functions, black).\
(E) Normalized ACTB, IFITM1, BCL2, and IL10RA transcript expression of single cells using tSNE plot representation.\
See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1568955-f0003){#F3}

![scRNA-Seq of B Cell Subsets of HIV-1 Env-Immunized Neonatal and Adult Rhesus Macaques\
(A) Two-dimensional plot from unsupervised clustering by tSNE of the single-cell transcriptomes of the B cell cluster (MS4A1-and/or CD19-expressing cells) isolated from three neonate (blue) and three adult (red) rhesus macaques after the second immunization. 9,041 single cells are shown. The number of differentially expressed transcripts (likelihood ratio test, p ≤ 0.05) upregulated or downregulated in neonatal B cells is shown.\
(B) Transcripts upregulated in neonate B cells cluster in three functional groups (BCR activation and proliferation, red; antigen presentation, purple; naive/marginal zone and B cell inhibition, blue). Each circular node displays gene name.\
(C--E) Normalized transcript expression of single cells using tSNE plot representation. Examples of transcripts involved in (C) B cell activation, (D) marginal zone B cells, and (E) naive lymphocytes and inhibitory molecules.\
(F) Normalized transcript expression of MS4A1 and CXCR4 on tSNE plot representation. Legends indicate normalized transcript values. Overlay plot on the right labels MS4A1-expressing cells in red, CXCR4-expressing cells in blue, and co-expressing cells in green.](nihms-1568955-f0004){#F4}

![Frequency of B Cell Subsets in Peripheral Blood of HIV-1 Env-Immunized Neonatal and Adult Macaques\
Frequency of eight B cell subsets, including naive, IgM^+^ memory, IgG^+^ memory, IgM^−^ IgG^−^ memory, IgM^+^ plasmablasts, IgM^−^ plasmablasts, marginal zone-like (in log scale), and a rare population of undefined B cells (Query 1; Ki67^+^CD1c^+^CD27^+^ IgM^2+^) among CD20^+^CD3^−^ CD14^−^ CD16^−^ lymphocytes from CH505-SOSIP-immunized neonatal (blue) and adult (red) macaques in studies 2 and 3 measured by flow cytometry 2 weeks after the first, third, and sixth immunizations. Horizontal bars represent the group mean. nparLD was performed on SOSIP-immunized animals combined in studies 2 and 3 (p = 0.007 for naive, p = 0.69 for IgM^+^ memory, p = 0.0005 for IgG^+^ memory, p = 0.0002 for IgM^−^ IgG^−^ memory, p = 0.027 for IgM^+^ plasmablasts, p = 0.04 for IgM plasmablasts, p = 0.00009 for marginal zone-like, and p = 0.0007 for Query 1). The scales of the y axis are different on each graph.](nihms-1568955-f0005){#F5}

![Increased Frequencies of Activated Blood T Follicular Helper-like (Tfh) Cells in Neonates Compared to Adults\
The frequency of T cell subsets from CH505-SOSIP-immunized neonatal (blue) and adult (red) macaques in studies 2 and 3 measured by flow cytometry 2 weeks after the first, third, and sixth immunizations. CD4^+^ T cells, p = 0.017; naive CD4^+^ T cells, p = 0.002; central memory (CM) CD4^+^ T cells, p \> 0.05; effector memory (EM) CD4^+^ T cells, p = 0.006; CD8^+^ T cells, p = 0.016; naive CD8^+^ T cells, p \> 0.05; CM CD8^+^ T cells, p \> 0.05; EM CD8^+^ T cells, p = 0.005; Treg cells, p \> 0.05; circulating Tfh (cTfh) cells, p \> 0.05; and activated cTfh cells (ICOS^hi^Ki67^+^, p = 0.003; ICOS^hi^ CD69^+^, p = 0.002). Horizontal bars are the group mean. nparLD was performed on SOSIP-immunized animals combined in studies 2 and 3.](nihms-1568955-f0006){#F6}

![Compositions of Fecal Microbiota in Neonatal Rhesus Macaques, Unrelated Adult Rhesus Macaques, and Dams (Moms)\
(A) The 16S rRNA amplicons of the stool samples from neonatal and adult rhesus macaques and dams were pyrosequenced and classified by comparison with the database at the phylum and genus levels. The relative proportions of the microbial taxa classified are plotted against time.\
(B) Rarefaction curves plotted for phylogenetic distance as measures of alpha diversity.](nihms-1568955-f0007){#F7}

###### 

KEY RESOURCES TABLE

  ---------------------------------------------------------------------------------------------------------------------------------------
  REAGENT or RESOURCE                                          SOURCE                          IDENTIFIER
  ------------------------------------------------------------ ------------------------------- ------------------------------------------
  Antibodies                                                                                   

  Mouse anti-Human PD-1 Brilliant Violet 421, Clone EH12.2H7   Biolegend                       Cat\# 329920; RRID:AB_10960742

  Live/Dead Fix Aqua                                           Thermo Fisher Scientific        L34957

  Mouse anti-Human CD8a Brilliant Violet 570, Clone RPA-T8     Biolegend                       Cat\# 301038; RRID:AB_2563213

  Rat anti-Human\* CCR7 Brilliant Violet 605, Clone 3D12       BD Biosciences                  Cat\# 563711; RRID:AB_2738385

  Mouse anti-Human CD25 Brilliant Violet 650, Clone BC96       Biolegend                       Cat\# 302634; RRID:AB_2563807

  Mouse anti-Human CD4 Brilliant Violet 711, Clone OKT4        Biolegend                       Cat\# 317440; RRID:AB_2562912

  Mouse anti-Human CD45RA Brilliant Violet 786, Clone 5H9      BD Biosciences                  Cat\# 741010; RRID:AB_2740633

  Armenian Hamster anti-human ICOS BB515, Clone C398.4A        BD Biosciences                  Cat\# 565880; RRID:AB_2744480

  Mouse anti-Human CCR6 BB700, Clone 11A9                      BD Biosciences                  Cat\# 566477; RRID:AB_2744303

  Mouse anti-Human Bcl-6 PE, Clone K112--91                    BD Biosciences                  Cat\# 561522; RRID:AB_10717126

  Mouse anti-Human CD183 PE-CF594, Clone 1C6/CXCR3             BD Biosciences                  Cat\# 562451; RRID:AB_11153118

  Mouse anti-Human CD69 PE-Cy5, Clone FN50                     Biolegend                       Cat\# 310908; RRID:AB_314843

  Mouse anti-Human CD185 PE-Cy7, Clone MU5UBEE                 eBioscience\                    Cat\# 25--9185-42; RRID:AB_2573540
                                                               (Thermo Fisher Scientific)      

  Rat anti-Human Foxp3 APC, Clone PCH101                       eBioscience\                    Cat\# 17--4776-42; RRID:AB_1603280
                                                               (Thermo Fisher Scientific)      

  Mouse anti-Human Ki-67 Alexa Fluor 700, Clone B56            BD Biosciences                  Cat\# 561277; RRID:AB_10611571

  Mouse anti-human CD3 APC-Cy7, Clone SP34--2                  BD Biosciences                  Cat\# 557757; RRID:AB_396863

  Live/Dead Fix Aqua                                           Thermo Fisher Scientific        L34957

  Mouse anti-Human IgM Brilliant Violet 605, Clone G20--127    BD Biosciences                  Cat\# 562977; RRID:AB_2737928

  Mouse anti-Human CD16 Brilliant Violet 650, Clone 3G8        Biolegend                       Cat\# 302036; RRID:AB_2632790

  Mouse anti-Human CD3 Brilliant Violet 650, Clone SP34--2     BD Biosciences                  Cat\# 563916; RRID:AB_2738486

  Mouse anti-Human CD14 Brilliant Violet 650, Clone M5E2       BD Biosciences                  Cat\# 563419; RRID:AB_2744286

  Mouse anti-Human CD27 Brilliant Violet 711, Clone O323       Biolegend                       Cat\# 302834; RRID:AB_2563809

  Mouse anti-Human CD20 Brilliant Violet 785, Clone 2H7        Biolegend                       Cat\# 302356; RRID:AB_2566316

  Mouse anti-Human CD38 FITC, Clone OKT10                      Caprico Biotechnologies         Cat\# 100815

  Mouse anti-Human CD72 PerCP, Clone Bu40                      Novus Biologicals               Cat\# NB100--64350PCP

  Mouse anti-Human Bcl6 PE, Clone K112--91                     BD Biosciences                  Cat\# 561522; RRID:AB_10717126

  Mouse anti-Human CD1c PE-Dazzle594, Clone L161               Biolegend                       Cat\# 331532; RRID:AB_2565293

  Mouse anti-Human CD69 PE-Cy5, Clone FN50                     Biolegend                       Cat\# 310908; RRID:AB_314843

  Mouse anti-Human CD21 PE-Cy7, Clone B-ly4                    BD Biosciences                  Cat\# 561374; RRID:AB_10681717

  Mouse anti-Human Ki67 Alexa Fluor 700, Clone B56             BD Biosciences                  Cat\# 561277; RRID:AB_10611571

  Mouse anti-Human IgG APC-H7, Clone G18--145                  BD Biosciences                  Cat\# 561297; RRID:AB_10611877

  CH106                                                        Isolated from patient\          N/A
                                                               ([@R75])                        

  Goat Anti-Rhesus IgG(H+L)-FITC                               Southern Biotech                Cat\# 6200--02; RRID:AB_2796265

  RD1-conjugated anti-p24                                      KC57, Beckman Coulter           Cat\# 6604667; RRID:AB_1575989

  CD14 (BV570)                                                 Biolegend                       Cat\# 301832; RRID:AB_2563629

  CD16 (PE-Cy7)                                                BD Biosciences                  Cat\# 557744; RRID:AB_396850

  CD3 (PerCP Cy5.5)                                            BD Biosciences                  Cat\# 552852; RRID:AB_394493

  CD20 (FITC),                                                 BD Biosciences                  Cat\# 347673; RRID:AB_400338

  CD27 (APC-Cy7)                                               Biolegend                       Cat\# 302816; RRID:AB_571977

  IgD (PE)                                                     Southern Biotech                Cat\# 2030--09; RRID:AB_2795630

                                                                                               

  Bacterial and Virus Strains                                                                  

  HIV-1 strain CH505TF, GENBANK: KC247556                      Isolated from patient\          N/A
                                                               ([@R75])                        

  HIV-1 strain CH505.w4.3, GENBANK: KC247557                   Isolated from patient\          N/A
                                                               ([@R75])                        

  HIV-1 strain MW965.26, GENBANK: U08455                       Isolated from patient\          N/A
                                                               ([@R44])                        

  HIV-1 strain SF162.LS, GENBANK: EU123924                     Isolated from patient\          N/A
                                                               ([@R75])                        

  HIV-1 strain 6644.V2.C33, GENBANK: HM215336                  Isolated from patient\          N/A
                                                               ([@R46])                        

  HIV-1 strain DJ263.8, GENBANK: EU855130                      Isolated from patient\          N/A
                                                               ([@R73])                        

  HIV-1 strain 45_01dG5, GENBANK: JQ609687                     Isolated from patient\          N/A
                                                               ([@R152])                       

  HIV-1 strain JR-FL, GENBANK: AY669728                        Isolated from patient\          N/A
                                                               ([@R13])                        

  HIV-1 strain Q842.D12, GENBANK: AF407160                     Isolated from patient\          N/A
                                                               ([@R78])                        

  HIV-1 strain 57128.vrc15, AY736829                           Isolated from patient\          N/A
                                                               ([@R78])                        

  HIV-1 strain YU2, GENBANK: M93258                            Isolated from patient\          N/A
                                                               ([@R72])                        

  HIV-1 strain ZM17635F.66                                     Undetermined                    N/A

  HIV-1 strain Q168.A2, GENBANK: AF407148                      Isolated from patient\          N/A
                                                               ([@R78])                        

  HIV-1 strain BG1168.1, GENBANK: AY835443                     Isolated from patient\          N/A
                                                               ([@R71])                        

  Murine Leukemia virus: SVA-MLV                               Negative Control Virus          NIH AIDS Reagent Program: catalog\# 1065

  HIV-1 strain CNE55, GENBANK HM215418                         Isolated from patient\          N/A
                                                               ([@R46])                        

  HIV-1 strain TRO.11, GENBANK AY835445                        Isolated from patient\          N/A
                                                               ([@R71])                        

  HIV-1 strain SC422661.8, GENBANK AY835441                    Isolated from patient\          N/A
                                                               ([@R71])                        

  MuLV + Kifunensine                                           this paper                      N/A

  HIV-1 strain JR-FL + Kifunensine                             JR-FL + Kifunensine\            N/A
                                                               ([@R35])                        

  HIV-1 strain JR-FL.ADIR.4 + Kifunensine                      JR-FL mutant + Kifunensine\     N/A
                                                               (Saunders et al., 2017)         

  HIV-1 strain JR-FL.GAIR.4 + Kifunensine                      JR-FL mutant + Kifunensine\     N/A
                                                               (Saunders et al., 2017)         

  HIV-1 strain JR-FL.GDAR.2 + Kifunensine                      JR-FL mutant + Kifunensine\     N/A
                                                               (Saunders et al., 2017)         

  HIV-1 strain JR-FL.GDIA.3 + Kifunensine                      JR-FL mutant + Kifunensine\     N/A
                                                               (Saunders et al., 2017)         

  HIV-1 strain JR-FL.GAIA.4 + Kifunensine                      JR-FL mutant + Kifunensine\     N/A
                                                               (Saunders et al., 2017)         

                                                                                               

  Biological Samples                                                                           

  Plasma and PBMCs from macaques in study\                     this paper                      
  no.1+A80:C82                                                                                 

  Plasma and PBMCs from macaques in study no.2                 this paper                      

  Plasma and PBMCs from macaques in study no.3                 this paper                      

                                                                                               

  Chemicals, Peptides, and Recombinant Proteins                                                

  soluble CD4                                                  NIH AIDS Repository             Cat \#4615

  Expi293 media                                                Invitrogen                      Cat \#A1435102

  Expifectamine                                                Life Technologies               Cat \#A14524

  Protein A beads                                              Pierce                          Cat \#PI-20334

  Vivaspin 15                                                  Sartorius Stedim                Cat \#VS15T22

  Vivaflow 50                                                  Sartorius Stedim                Cat \#VF05P2

  AmpliTaq Gold 360 Mastermix                                  Applied Biosystems by Thermo\   Cat \#4398881
                                                               Fisher Scientific               

  d7_HIV_gp120_CH0505 T/F_Atb_SavAF647                         [@R147]                         N/A

  d7_HIV_gp120_CH0505 T/F_Atb_SavBV421                         [@R147]                         N/A

  d7_HIV_gp120_CH0505 T/F_Atb_SavAF647                         [@R147]                         N/A

  d7_HIV_gp120_CH0505 T/F_Atb_SavBV421                         [@R147]                         N/A

  CH505_TF D7 gp120/293F/Mon                                   [@R147]                         N/A

  CH0505 TF gp120 d371I                                        [@R147]                         N/A

  ch505TF SOSIP 664 v4.1                                       [@R114]                         N/A

  ch505wk100 SOSIP 664 v4.1                                    [@R114]                         N/A

                                                                                               

  Experimental Models: Cell Lines                                                              

  Human cell line TZM-bl                                       NIH ARRRP                       Cat \#8129

  Human cell line Expi293F                                     Invitrogen                      Cat \#14527

  monocytic THP-1 cell line                                    ATCC                            Cat \#TIB-202

  CEM.NKRCCR5 cells                                            NIH AIDS Repository             Cat \# 4376

                                                                                               

  Recombinant DNA                                                                              

  pcDNA3.1/hygromycin (+)                                      Invitrogen                      Cat \# V87020

                                                                                               

  Software and Algorithms                                                                      

  Diva                                                         BD Biosciences                  N/A

  FlowJo (version 9.9.4)                                       FlowJo, LLC                     N/A

  GraphPad Prism (version 7.0)                                 GraphPad Software               N/A

  CellRanger                                                   [@R156]                         N/A

  Seurat                                                       [@R113]                         N/A

  SAS v9.4                                                     SAS Institute                   N/A

  Cloanalyst Program                                           [@R63]                          N/A

  QIIME v. 1.9.1                                               [@R21]                          N/A

  vsearch v. 1.11.1                                            [@R108]                         N/A

  LEfSe (Linear discriminant analysis effect size)             [@R119]                         N/A
  ---------------------------------------------------------------------------------------------------------------------------------------

###### Highlights

-   Neonatal immunity to HIV-1 Env immunogens, including soluble trimers (SOSIP)

-   Neonatal Env immunity to DNA or protein-based vaccine platforms

-   Neonatal immune cells have distinct transcriptome profiles from adults

-   Microbial imprinting of the B cell repertoire can occur within a week of birth
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